Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Perspective Therapeutics, Inc.ISR · Entity 694 | Director | February 21, 2023 | February 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Perspective Therapeutics, Inc.
Report date February 21, 2023 · Filed February 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2033-02-21 | Direct | 894,615 |
Reported balance
After 2023-02-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-21 · Grant · Acquired 470,000 · Balance 894,615 F1: Vest monthly over three years. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2033-02-21 | Direct | 1,124,615 |
Reported balance
After 2023-02-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-21 · Grant · Acquired 230,000 · Balance 1,124,615 F2: 100% vests 2/21/2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Vest monthly over three years.
F2: 100% vests 2/21/2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2023 Filed Feb 24, 2023 00:32 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 230,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001437749-23-004432 · rdgdoc.xml · derivative · entry 2 McCormick Michael W · CIK 0001333527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,124,615 Underlying: Common Stock · 230,000 shares Expires 2033-02-21 F2 · derivative.exercise_date: 100% vests 2/21/2024. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 00:32 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 470,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001437749-23-004432 · rdgdoc.xml · derivative · entry 1 McCormick Michael W · CIK 0001333527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 894,615 Underlying: Common Stock · 470,000 shares Expires 2033-02-21 F1 · derivative.exercise_date: Vest monthly over three years. Read SEC document |
| July 21, 2022 Filed Jul 29, 2022 22:28 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 135,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001437749-22-018156 · rdgdoc.xml · derivative · entry 1 McCormick Michael W · CIK 0001333527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,615 Underlying: Common Stock · 135,000 shares Expires 2032-07-21 F1 · derivative.exercise_date: One-third vested on 7/21/2022, and the remaining two-thirds will vest over the next two (2) years, commencing on 7/21/2023, until fully vested. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:19 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 135,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001437749-21-016441 · rdgdoc.xml · derivative · entry 1 McCormick Michael W · CIK 0001333527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,615 Underlying: Common Stock · 135,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: One-third vested on 7/1/2021, and the remaining two-thirds will vest over the next two (2) years, commencing on 7/1/2022, until fully vested. Read SEC document |
| October 22, 2020 Filed Oct 28, 2020 20:40 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseWarrant (right to buy) · Derivative | 9,615 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001437749-20-021853 · rdgdoc.xml · derivative · entry 2 McCormick Michael W · CIK 0001333527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,615 Underlying: Common Stock · 9,615 shares Expires 2025-10-22 F2 · shares: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. F2 · derivative.exercise_date: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. F2 · derivative.expiration_date: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. Read SEC document |
| October 22, 2020 Filed Oct 28, 2020 20:40 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 19,230 | $0.52 | $9,999.60 |
DisclosureSEC source: 0001437749-20-021853 · rdgdoc.xml · nonDerivative · entry 1 McCormick Michael W · CIK 0001333527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,230 F1 · shares: Purchased pursuant to public offering that closed on October 22, 2020. F1 · price: Purchased pursuant to public offering that closed on October 22, 2020. Read SEC document |
| June 23, 2020 Filed Jul 15, 2020 21:11 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001437749-20-015202 · rdgdoc.xml · derivative · entry 1 McCormick Michael W · CIK 0001333527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: 25% vested as of 6/23/2020, and the remaining 75% will vest over the next three (3) years, commencing on 6/23/2021, until fully vested. Read SEC document |
| June 18, 2019 Filed Jun 24, 2019 20:54 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001437749-19-012550 · rdgdoc.xml · derivative · entry 1 McCormick Michael W · CIK 0001333527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 30,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: 25% vested as of 6/18/2019, and the remaining 75% will vest over the next three (3) years, commencing on 6/18/2020, until fully vested. Read SEC document |
| July 18, 2018 Filed Jul 26, 2018 01:13 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001437749-18-013774 · rdgdoc.xml · derivative · entry 1 McCormick Michael W · CIK 0001333527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 25,000 shares Expires 2028-07-18 F1 · derivative.exercise_date: 25% vested as of 7/18/2018, and the remaining 75% will vest over the next three (3) years, commencing on 7/18/2019, until fully vested. Read SEC document |
| June 26, 2018 Filed Jul 2, 2018 21:18 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001437749-18-012802 · rdgdoc.xml · derivative · entry 1 McCormick Michael W · CIK 0001333527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-26 F1 · derivative.exercise_date: 25% vested as of 6/26/2018, and the remaining 75% will vest over the next three (3) years, commencing on 6/26/2019, until fully vested. Read SEC document |
| June 27, 2017 Filed Jun 30, 2017 01:05 UTC Amendment | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001642247-17-000016 · primary_doc.xml · derivative · entry 1 McCormick Michael W · CIK 0001333527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: 25% vested as of 6/27/2017, and the remaining 75% will vest over the next three (3) years, commencing on 6/27/2018, until fully vested. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:26 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001642247-17-000013 · primary_doc.xml · derivative · entry 1 McCormick Michael W · CIK 0001333527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: 25% vested as of 6/27/2017, and the remaining 75% will vest over the next three (3) years, commencing on 6/27/2018, until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.